US Patent Issued to Horizon Therapeutics Ireland DAC on Jan. 28 for "Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases" (Irish Inventors)

ALEXANDRIA, Va., Jan. 29 -- United States Patent no. 12,209,123, issued on Jan. 28, was assigned to Horizon Therapeutics Ireland DAC (Ireland).

"Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases" was invented by Anna Hansen (Dublin), Xiaodong Xiao (Dublin), Peter Pavlik (Dublin), Yan Chen (Dublin) and Catherine Rachel Ettinger (Dublin).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are anti-FLT3L antibodies and methods of using the antibodies to treat autoimmune and other inflammatory diseases."

The patent was filed on July 21, 2022, under Application No. 17/814,075.

*For further info...